|  | | Latest Updates |  | |
 | | Archive |  |  |  |  | Fast Takes, the "quad" pill, ARV generics, Truvada/PrEP approval. October 5, 2012. |  |  |  | Pitavastatin and Darunavir/Ritonavir, research brief. October 5, 2012. |  |  |  | Dolutegravir in Initial Therapy: Two Phase 3 Studies, research brief. October 5, 2012. |  |  |  | Cobicistat as a PK Booster of Atazanavir, research brief. October 5, 2012. |  |  |  | Elvitegravir as Effective as Raltegravir in Treatment-Experienced Patients, research brief. October 5, 2012. |  |  |  | Updates to the Database of ARV Drug Interactions, reference table. May-October, 2012. |  |  |  | More on Protease Inhibitors and Corticosteroids, research brief. May 18, 2012. |  |  |  | More on Interactions between Darunavir and Pravastatin: To Use or Not to Use?, research brief. May 18, 2012. |  |  |  | Fast Takes, fosamprenavir, etravirine. May 17, 2012. |  |  |  | ARV Interactions with HCV Protease Inhibitors, reference table and overview. April 30, 2012. |  |  |  | Updates to the Database of ARV Drug Interactions, reference table. January-April, 2012. |  |
 | | Winter 2011-12 |  |  |  |  | Research Briefs: Once-Daily Etravirine; Switching from Efavirenz to Rilpivirine; Darunavir + Raltegravir without NRTIs, Revisited
|  |  |  | Fast Takes: Rilpivirine Added to DHHS Recommendations; Raltegravir-Associated Skin Reactions; Darunavir Oral Suspension
|  |
|
 | | Summer 2011 |  |  |  |  | Interactions: Buprenorphine/Naloxone with Raltegravir; Pitavastatin with Lopinavir/Ritonavir; Sustained Effect of Efavirenz on Rilpivirine Serum Concentrations; Hepatitis C NS3 Protease Inhibitors and Antiretroviral Drugs |  |  |  | Research Briefs: Preexposure Prophylaxis with Oral Tenofovir or Tenofovir/Emtricitabine; Dolutegravir in Treatment-Naive Patients; Lersivirine: A New NNRTI
|  |  |  | Fast Takes: Rilpivirine approved; 1-pill, once-daily combination regimen: rilpivirine/tenofovir/emtricitabine; Etravirine 200 mg tablet approved; HCV drug approvals
|  |  |  | Reference Table: Updates to the Database of ARV Drug Interactions |  |
|
 | | Winter/Spring 2011 |  |  |  |  | Research Briefs: Darunavir + Raltegravir without NRTIs; Raltegravir: Inferior Results with Once-Daily Dosing; Hepatitis C Infection and Telaprevir; Rilviripine Redux |  |  |  | Fast Takes: Darunavir dosage in treatment-experienced patients
|  |  |  | Reference Table: Updates to the Database of ARV Drug Interactions |  |
|
 | | Spring/Summer 2010 |  |  |  |  | Interactions: Rosuvastatin Levels Increased by Ritonavir-Boosted Darunavir; Fosamprenavir and Posaconazole |  |  |  | Research Briefs: Recent Advances in Once-Daily Therapies and Fixed-Dose Combination Regimens: Rilpivirine (TMC278) in Initial Therapy; S/GSK 572 in Initial Therapy: Interim Results of SPRING-1; Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir ("Quad" Pill) in Initial Therapy; Novel Pharmacokinetic Booster Cobicistat (GS-9350) |  |  |  | Fast Takes: Maraviroc in patients with kidney disease; Didanosine and noncirrhotic portal hypertension |  |  |  | Reference Table: Updates to the Database of ARV Drug Interactions |  |
|
 | | Winter 2010 |  |  |  |  | Interactions: Efavirenz and Levonorgestrel; Lopinavir/ritonavir and Buprenorphine |  |  |  | Research Briefs: Vicriviroc in Treatment-Experienced Patients |  |  |  | Fast Takes: Ritonavir tablet formulation; Maraviroc approved for initial therapy; Saquinavir/ritonavir and possible risk of abnormal heart rhythms |  |  |  | Reference Table: Updates to the Database of ARV Drug Interactions |  |
|
 | | Fall 2009 |  |  |  |  | Research Briefs: Kaletra Dosage Adjustment for Patients on Efavirenz or Nevirapine; Once-Daily Raltegravir; Atazanavir and Lopinavir/Ritonavir in Hemodialysis |  |  |  | Reference Table: Updates to the Database of ARV Drug Interactions |  |
|
 | | Summer 2009 |  |  |  |  | Research Briefs: Regimen Simplification: Atazanavir vs Atazanavir/Ritonavir; Atazanavir/Ritonavir in Pregnancy; Investigational Integrase Inhibitor Shows Potent Activity in Early Studies |  |  |  | Reference Table: Updates to the Database of ARV Drug Interactions |  |  |  | Fast Takes: Raltegravir approved for initial therapy |  |
|
 | | Spring 2009 |  |  |  |  | Research Briefs: Rosiglitazone and Heart Disease; Antipsychotics and Sudden Cardiac Death; New Pharmacokinetic Booster on the Horizon; Interleukin-2: No Clinical Benefit; Raltegravir Substitution for Lopinavir/Ritonavir (SWITCHMRK Study); Abacavir and Myocardial Infarction Risk: Additional Data |  |  |  | Reference Table: Updates to the Database of ARV Drug Interactions |  |  |  | Fast Takes: Darunavir: Traditional approval |  |  |  | Guidelines: New Guidelines: Adult OI prevention and treatment; Updated: Pediatric ARV guidelines; Updated: Perinatal guidelines |  |
|
 | | Winter 2009 |  |  |  |  | Research Briefs: Darunavir Approved for Use with Boosted Ritonavir as "Preferred" PI, Pediatric Dosing |  |  |  | Fast Takes: Recent news about maraviroc, abacavir: pediatric formulation, and abacavir/lamivudine: DHHS recommendations |  |
|
 | | Fall 2008 |  |  |  |  | Research Briefs: Pregabalin for Neuropathic Pain: Not More Effective Than Placebo; Abacavir/Lamivudine: Higher Rates of Virologic Failure in ARV-Naive Patients with HIV RNA ≥100,000 copies/mL compared with Tenofovir/Emtricitabine; Abacavir and Risk of Myocardial Infarction: The SMART Study |  |  |  | Interactions: Atazanavir: Interactions with Efavirenz, Nevirapine, and Oral Hormonal Contraceptives |  |  |  | Fast Takes: Recent news about ritonavir, darunavir, atazanavir + ritonavir, tenofovir, zidovudine, and didanosine |  |
|
 | | Summer 2008 |  |  |  |  | Research Briefs: Abacavir and Didanosine Associated with Increased Risk of Myocardial Infarction; Testing for Chemokine Coreceptor Tropism |  |  |  | Interactions: Rosuvastatin with Lopinavir/Ritonavir and Tipranavir; Rifampin and "Super-Boosted" Protease Inhibitors |  |  |  | Fast Takes: Recent news about nelfinavir, tipranavir, lopinavir/ritonavir, and nevirapine |  |
|
 | | Spring 2008 |  |  |  |  | Research Briefs: Atazanavir Efficacy Data and Changes in Dosage Recommendations; Raltegravir Substitution for Enfuvirtide; HLA-B*5701 Screening |  |  |  | Reference Table: Etravirine-ARV Interactions |  |  |  | Fast Takes: Recent news about darunavir, lamivudine, lopinavir/ritonavir and amprenavir |  |
|
|
|